Navigation Links
Researchers engineer pancreatic cell transplants to evade immune response
Date:12/31/2008

In a finding that could significantly influence the way type 1 diabetes is treated, researchers at Albert Einstein College of Medicine of Yeshiva University have developed a technique for transplanting insulin-producing pancreatic cells that causes only a minimal immune response in recipients.

At present, cell transplantation therapy is limited because transplant recipients are forced to take powerful immunosuppressant medications that have toxic side effects and raise the risk of infection. This advance in mice, described in the online version of Gene Therapy, could pave the way for routine use of cell transplants as a therapy for type 1 diabetes in humans.

Type 1 diabetes is an incurable autoimmune disease in which the immune system mistakenly destroys the body's own pancreatic beta cells. Beta cells produce insulin, which breaks down sugar, or glucose, for use by the body. Without these cells, too much glucose builds up in the blood. High blood glucose levels damage cells and can eventually lead to complications such as heart disease, kidney disease, blindness, and premature death.

Type 1 diabetes affects up to 2.4 million Americans and can develop at any age, though it typically appears during childhood or adolescence. People with type 1 diabetes must closely monitor their blood glucose levels and take daily insulin injections for life.

A promising alternative to insulin injections is cellular transplantation, in which beta cells are harvested from cadavers and injected into the bloodstream of patients with diabetes; the new cells replace the recipients' destroyed pancreatic beta cells. Although such transplants can control type 1 diabetes, recipients must take immunosuppressant medications in order to prevent rejection of these beta foreign cells. "Ultimately, even with immunosuppressive therapy, most of these individuals end up rejecting the transplanted cells," says the study's principal investigator, Harris Goldstein, M.D., professor of pediatrics and of microbiology & immunology at Einstein.

In this study, Dr. Goldstein and his colleagues devised a way to make foreign beta cells invisible to a transplant recipient's immune system, dramatically protecting them from rejection. They did so by harnessing the innate ability of adenoviruses to evade the body's immune surveillance system. (Adenoviruses infect tissues that line the respiratory tract, eyes, intestines, and urinary tract). After infecting cells, adenoviruses produce proteins that prevent the cells from signaling the immune system that they have been infected and should be destroyed. The viruses also produce proteins that can turn off a cell's built-in self-destruct mechanism, which is usually triggered when something disturbs a cell's internal functions.

The researchers began with a special line of insulin-producing beta cells, developed at Einstein, that were harvested from mice. When injected into diabetic mice, these foreign cells can restore normal glucose control, but only temporarily. The transplanted cells are soon destroyed by the mouse's immune system and glucose levels begin to rise, returning to pre-transplant disease levels.

Dr. Goldstein and his colleagues genetically engineered these beta cells to include three adenoviral genes responsible for making immunosuppressive proteins. Diabetic mice that received these engineered foreign beta cells maintained normal glucose control for up to three months. In contrast, a control group of diabetic mice that received the regular foreign beta cells exhibited normal glucose control for just a few days.

"Clearly, the three proteins were not optimal, because ultimately the cells did get rejected," says Dr. Goldstein. "We are now looking at other viral genes that also contribute to immune suppression and are trying to identify the best gene combination to use."

Dr. Goldstein views the current experiment as a proof of concept. "We were able to demonstrate that genetically engineered beta cells can be made highly resistant to rejection and can basically correct diabetes. This technique could conceivably be applied to protect any type of cellular transplant from rejection."

However, pancreatic cell transplantation could not help treat patients with type 2 diabetes. In this form of the disease, patients have fully functional beta cells but cells throughout their body become resistant to insulin.


'/>"/>

Contact: Mike Heller
mheller@aecom.yu.edu
718-430-4186
Albert Einstein College of Medicine
Source:Eurekalert

Related biology news :

1. UC Davis researchers find molecule that targets brain tumors
2. UT Public Health researchers find link to severe Staph infections
3. SUNY Downstate researchers find that memory storage molecule preserves complex memories
4. Researchers make breakthrough in the production of double-walled carbon nanotubes
5. Researchers find chink in the armor of viral tummy bug
6. Biomedical researchers create artificial human bone marrow in a test tube
7. Princeton researchers discover new type of laser
8. UT Southwestern researchers identify gene linked to inherited form of fatal lung disease
9. James Thomson receives 2008 Massry Prize honoring stem cell researchers
10. Researchers push nature beyond its limits to create higher-density biofuels
11. Researchers advance knowledge of little nano-machines in our body
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2018)... and CARDIFF, Wales (PRWEB) , ... August 30, ... ... Agency. Martha Sanchez, senior scientist, IBM Research. Jacklyn Novak, infrared materials engineer, LightPath ... Katherine Johnson, the NASA mathematician who just celebrated her 100th birthday. Today, they ...
(Date:8/29/2018)... ... August 28, 2018 , ... Fuzionaire ... emission tomography (PET), today launched its proprietary radiolabeling platform. Leveraging a fundamental ... study and cure debilitating diseases, earlier, and with unprecedented precision. The platform ...
(Date:8/26/2018)... ... 25, 2018 , ... Maire Mayne, an evidence-based energy healer, ... to reduce inflammation and autoimmune disorders and improve overall immune response. , The ... The following data was reported:,     Over 180% increase in ...
Breaking Biology News(10 mins):
(Date:9/7/2018)... ... September 06, 2018 , ... ... September 25th-28th is a meeting of “The industry’s preeminent event on novel drug ... discovery scientists powerful tools to study these emerging targets in a quest to ...
(Date:9/1/2018)... , ... August 31, 2018 , ... ... results of the impact of a proprietary biofield energy treated nutraceutical supplement used ... biomarkers for immune function response and blood, as well as, organ-specific inflammation. The ...
(Date:8/29/2018)... ... August 28, 2018 , ... Cognition Corporation ®, a ... of talks for NAVIGATE2018 . , Ryan Ward, Director of Engineering at ... user conference. An experienced engineer and manager with Zimmer Biomet for almost 15 years, ...
(Date:8/29/2018)... ... 28, 2018 , ... USDM Life Sciences , the leading risk management, ... announces that Manu Vohra will deliver a presentation at the BoxWorks 2018 ... Box for GxP in 30 Days” , When: Thursday, August 30, 1:00-1:50 PM PT, ...
Breaking Biology Technology: